Trials / Not Yet Recruiting
Not Yet RecruitingNCT05136963
Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance
Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance Using Limited Sample Strategy for the Evaluation of Kidney Donation Candidates.
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In kidney transplantation, donor selection is based in part on the assessment of the functional capacity of the kidneys. For this purpose, it is recommended to measure the glomerular filtration rate (GFR) by a reference technique. To estimate GFR, several approaches are possible depending on the type of measurement (urinary or plasma) and the marker (exogenous or endogenous) used. Among these methods, the measurement of inulin clearance has long been considered the reference method. The occurrence of anaphylactic reactions led to its withdrawal from the market. Iohexol, an iodinated contrast agent, has characteristics similar to inulin. It is eliminated by glomerular filtration and its biological determination is simple. Nevertheless, the techniques currently used to calculate plasma clearance of Iohexol have been imperfectly validated and are not always easy to implement in practice. the investigators propose to develop a Bayesian estimator for estimating Iohexol clearance applied to a population of healthy subjects, representative of potential kidney donors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iohexol | 5 milliliter of iohexol will be administrated. |
| BIOLOGICAL | pharmacokinetics | 10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00 |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2021-11-30
- Last updated
- 2024-04-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05136963. Inclusion in this directory is not an endorsement.